

1

2

3 *Bacterial shedding and serologic responses following an outbreak of Salmonella Typhi in an endemic*
4 *cohort.*

5

6 Peter Johnston^{1*}, Patrick Bogue², Angeziwa Chunga Chirambo², Maurice Mbewe², Reenesh Prakash²,

7 Vanessa Kandoole-Kabwere², Rebecca Lester², Thomas Darton¹, Stephen Baker³, Melita Gordon²,

8 James Meiring^{1,2}

9

10 1. Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield,
11 United Kingdom.

12 2. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.

13 3. Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of
14 Cambridge, United Kingdom.

15

16 *Corresponding author. E-mail: p.i.johnston@sheffield.ac.uk

17 *Running title: Bacterial shedding and serologic responses after a typhoid outbreak.*

18

19

20

21

22 Abstract

23 *Background*

24 *Salmonella enterica* serovar Typhi (*S. Typhi*), the causative agent of Typhoid fever, is transmitted
25 faecal-orally. Some typhoid sufferers shed *S. Typhi* beyond convalescence, but culturing stool
26 following every case is impractical. Here we hypothesised that serology might direct testing and
27 identify shedding after a typhoid outbreak.

28 *Methodology/Principle Findings*

29 In 2016 there was a typhoid outbreak in a Nursing School in Malosa, Malawi. We collected serum
30 three and six-months post-outbreak. We measured IgG antibody titres against Vi capsular
31 polysaccharide (anti-Vi IgG) and IgM / IgG antibodies against H:d flagellin (anti-H:d). We screened
32 faecal samples from participants with high and low anti-Vi IgG (measured at visit one) by culture and
33 PCR. Participants reported whether they had persistent fever for \geq three days (in keeping with World
34 Health Organization definitions for typhoid) during the outbreak. We tested for environmental *S.*
35 Typhi.

36 368 people provided serum at 3-months, of whom 320 provided serum at 6-months; 49 participants
37 provided a faecal sample (25 from the highest and 24 from the lowest deciles for anti-Vi IgG titre).

38 We did not grow *S. Typhi* from faeces, but one sample produced a positive PCR amplification for *S.*
39 Typhi. Median anti-Vi IgG titre fell amongst participants with persistent fever (8.08 to 3.7 EU/ml,
40 <0.000001 , *Wilcoxon signed rank*). Median anti-H:d IgG titres fell in those with and without
41 persistent fever (87.8 to 77.4 EU/, $p = <0.000001$ and 82.4 to 79.2 EU/ml, $p = 0.0002$, *Wilcoxon*
42 *signed rank, respectively*). Anti-H:d IgM titres did not change significantly. Non-Typhoidal
43 Salmonellae were identified in water sampled at source and a kitchen tap.

44 *Conclusions / Significance*

45 We did not identify culture-confirmed shedding through sero-surveillance. Serologic trends signify a
46 fall from an outbreak-associated peak. Despite effective vaccines, identifying ways to detect and treat
47 shedding remain vital to break transmission and eliminate typhoid.

48 Author Summary

49 Typhoid fever spreads by the faecal-oral route. Some people continue to shed the bacterium that
50 causes typhoid (*Salmonella enterica* serovar Typhi, or *S. Typhi*) after recovering from the illness. To
51 stop onward spread it is important that these people are identified and treated.

52 Shedders are detected when *S. Typhi* grows from faeces, but it is not practical to obtain stool samples
53 from large populations. Following a typhoid outbreak we tested whether a subset of participants with
54 high antibodies to *S. Typhi* proteins contained more shedders than a subset with low antibody
55 responses. We tested whether antibody levels changed in the months after the outbreak, to inform
56 whether they are useful markers of exposure in a population.

57 We did not grow *S. Typhi*. This may be because our population had few risk factors for *S. Typhi*
58 carriage, or because exposure to other endemic bacteria influence antibody levels. We saw a decline
59 in antibody levels over time, most marked in those who reported fever during the outbreak. We think
60 that this reflects a response to recent infection. It is important to continue to evaluate ways of finding
61 carriers so that, combined with vaccines and improved sanitation, we can one day eliminate typhoid.

62

63 Background

64 It is estimated that 1.5 million cases of typhoid fever occurred in Sub-Saharan Africa in 2017 (1).
65 Whilst this figure represents a fall in incidence estimates from 1990, localised outbreaks (2-5) map
66 closely to the emergence of genotypes associated with multi-drug resistance (MDR) (6). Mathematical
67 modelling suggests such outbreaks may be driven by increased transmissibility associated with drug
68 resistance phenotypes (7). Where *Salmonella enterica* serovar Typhi (*S. Typhi*) is inadequately
69 treated, ongoing shedding becomes more likely, and detection of this is essential in order to break the
70 transmission cycle.

71 *S. Typhi* is shed intermittently in stool, and bacterial culture lacks sensitivity (8). A recent case-
72 control study of children living in Nairobi found *S. Typhi* carriage rates of 1.1% among asymptomatic

73 individuals (9). The relative contribution of temporary shedders to ongoing transmission remains
74 unclear, but is likely to play a larger role in high incidence settings (10, 11).

75 In non-endemic settings, serology has been exploited to complement an outbreak investigation, with
76 candidate shedders successfully identified by a high anti-Vi antibody titre (anti-Vi IgG) followed by
77 isolation of *S. Typhi* in stool (12, 13). Serology has been used in attempts to identify carriers in
78 endemic populations, but has shown limited success (14-16).

79 In June 2016 an outbreak of febrile illness occurred in Malosa, Malawi. Three patients presenting to
80 the local hospital had blood culture-confirmed typhoid fever. Cases were traced to a local primary
81 school, secondary school and a residential nursing school. Over the next month the District Health
82 Office identified 101/407 nursing school residents who met a clinical case definition for typhoid
83 fever.

84 Our primary objective was to identify nursing school residents shedding *S. Typhi* after the outbreak,
85 using serology to target subsequent testing of high risk individuals. We focussed our efforts on the
86 nursing school because students continuing to shed *S. Typhi* might transmit typhoid to patients.

87 Secondary objectives were to identify any environmental source of *S. Typhi* within the nursing school
88 and to explore serologic responses to typhoid exposure, as determined by self-reported, persistent
89 fever.

90

91 **Methods**

92 We performed a prospective observational study comprising two study visits, conducted three and six
93 months after the Malosa outbreak.

94 Any person over 18 years of age who had been resident in the nursing school between 1st June 2016
95 and 31st August 2016 was eligible to participate. We enrolled participants and conducted study visit
96 one simultaneously in October 2016, three months after the outbreak.

97 We collected a blood sample from each participant and completed a structured case record. This
98 included self-report of whether the participant had a persistent fever (defined as three days or more
99 duration) during the outbreak. Those with persistent fever were considered typhoid cases based on the
100 WHO case finding definition (17).

101 We identified participants whose three-month anti-Vi IgG levels were in the top ten percent of the
102 cohort and participants whose anti-Vi IgG were in the lowest ten percent of the cohort. These
103 participants were approached and asked to provide a stool sample. Samples were collected between
104 the three- and six-month study visits, after anti-Vi IgG results became available. Stool was sent for
105 culture and polymerase chain reaction (PCR) testing.

106 The entire cohort was approached again in January 2017, six months after the outbreak. A further
107 blood sample was obtained for repeat serology.

108 *Laboratory procedures*

109 We determined anti-Vi IgG antibody concentration using a commercial Enzyme-linked
110 immunosorbent assay (ELISA) in accordance with manufacturer's instructions (VaccZyme™ The
111 Binding Site, Birmingham, UK). We derived antibody concentration in ELISA units/ml (EU/ml) from
112 the optical density using a standardised curve-fitting logistic method.

113 Anti-H:d IgM and IgG were performed at the Oxford University Clinical Research Unit in Vietnam,
114 using in-house ELISAs, as previously described (18).

115 Stool samples were collected in sterile sample pots and transferred to the laboratory on the same day.
116 Stool was pre-enriched in Selenite broth before being sub-cultured on Xylose Lysine Deoxyxholate
117 (XLD) agar at 37°C for 18-24 hours. Single colonies from XLD were sub-cultured on MacConkey
118 and Sheep blood agar (SBA) plates. Colonies from SBA plates were used for biochemical tests.
119 Analytical Profile Index (API 20E) tests were used for *Salmonella* identification. Following the
120 White-Kauffmann-Le Minor scheme, serotyping was done using polyvalent O and H, O4, O9, Hd,
121 Hg, Hi, Hm, and Vi antisera (Pro-Lab Diagnostics).

122 PCR testing was used alongside routine culture to increase the yield from stool. DNA was extracted
123 from Selenite broth pre-enriched stool specimens using QIAamp Fast DNA Stool Mini Kit (Qiagen).
124 A pan *Salmonella* PCR targeting the *ttr* gene, encoding tetrathionate reductase, and a multiplex PCR
125 with a pan-*Salmonella* invasion A gene, *S. Typhi* fimbriae gene, and the kit's internal control were
126 performed (19, 20).

127

128 *Environmental sampling*

129 Malosa Dam provides water for the nursing school and secondary school via a gravity fed water pipe
130 feeding in to a holding tank. The water is reportedly chlorinated daily after leaving the holding tank.
131 We took 36 environmental samples, in-duplicate, over two days. These comprised stool from food-
132 handlers, food and tap water from the kitchens and water from the dam. Samples were cultured and
133 sero-typed as described above.

134 *Statistical methods*

135 We treated serologic data as a metric continuous variable, and our surrogate measure of typhoid
136 exposure as dichotomous (fever for ≥ 3 days or not).

137 We tested continuous variables for normality using the Shapiro-Wilks test before and after log-
138 transformation. We used nonparametric tests where data were not normally distributed.

139 We used paired significance tests to compare change in antibody titre within the population as a
140 whole and change in antibody titre depending upon whether the clinical definition for typhoid had
141 been met. We used unpaired significance tests to compare antibody titres between participants who
142 did and did not meet the WHO definition for typhoid at each study visit. Only participants who
143 submitted serum at three and six months contributed to paired analyses.

144 Statistical analyses were carried out using the free to use, open source statistical package 'R' version
145 4.1.1 (21). The significance threshold was set at 0.05 for all tests.

146

147 *Ethical considerations*

148 All participants provided written informed consent. Participant information materials were made
149 available in English and Chichewa languages. Our protocol stated that those who were stool culture
150 positive for *S. Typhi* would be advised by the District Health Office to take either 28 days of
151 ciprofloxacin or 14 days of azithromycin with the aim of eradicating carriage and preventing onward
152 transmission. This study was approved by College of Medicine Research Ethics Committee,
153 P.10/16/2043.

154

155 *Results*

156 We recruited 374 participants from a total population of 407. 368 participants submitted blood
157 samples three months post outbreak. 320 participants submitted blood at three months and six months.
158 We obtained stool samples from 25 of 36 participants whose anti-Vi IgG response was in the highest
159 decile, and from 24 of 36 participants whose anti-Vi IgG response was in the lowest decile. The
160 characteristics of included participants are shown in Table one.

161

162

163

164

165

166

167

168

169

170

	Clinical typhoid	No clinical typhoid	
Participants (N)	156	212	
Age in years (mean)	22.6	24.2	
(range)	8-54	18-42	
(SD)	4.4	6.3	
gender (proportion female, (%))	78/156 (50)	106/212 (50)	
Treated with antibiotics (%)	140/156 (90)	16/212 (7.5)	
Median anti-Vi IgG titre at visit one (EU/ml)	8.08 (IQR 17.9)	3.7 (IQR 12.4)	<i>P = 0.11 (Mann-Whitney-U test)</i>
Median anti-H:d IgM antibody titre at visit one (EU/ml)	55.2 (IQR 51.4)	52.1 (IQR 55.9)	<i>P = 0.34 (Mann-Whitney-U test)</i>
Median anti-H:d IgG antibody titre at visit one (EU/ml)	87.8 (IQR 85.1)	82.4 (IQR 88.4)	<i>P = 0.27 (Mann-Whitney-U test)</i>
Median anti-Vi IgG titre at visit two (EU/ml)	3.7 (IQR 17.7)	3.7 (IQR 14.4)	<i>P = 0.86 (Mann-Whitney-U test)</i>
Median anti-H:d IgM antibody titre at visit two (EU/ml)	54.2 (IQR 44.9)	55.3 (IQR 56.1)	<i>P = 0.92 (Mann-Whitney-U test)</i>
Median anti-H:d IgG antibody titre at visit two (EU/ml)	77.4 (IQR 57)	79.2 (IQR 65.7)	<i>P = 0.80 (Mann-Whitney-U test)</i>
Headache, N (%)	139/156 (89)	39/212 (18.4)	
Abdominal pain, N (%)	82/156 (52.6)	25/212 (11.8)	
Diarrhoea, N (%)	62/156 (39.7)	29/212 (13.7)	
Constipation, N (%)	31/156 (19.9)	10/212 (4.7)	
Nausea, N (%)	60/156 (38.5)	13/212 (6.1)	

171 *Table 1. Baseline characteristics of participants who submitted blood samples at study visit one*

172 *Stool Culture*

173 Of 49 participants who submitted stool for culture, none were culture positive for *S. Typhi* in stool.
174 Four participants had *Salmonella* spp. in stool on routine culture. Three of these participants were in
175 the lowest decile for anti-Vi IgG level at visit one, one was in the highest decile. None of the stool
176 samples grew *S. Typhi* (Figure 1). *Ttr* and multiplex PCR test did not detect any additional
177 *Salmonella* from the stool samples. One *Salmonella* isolate was identified as *S. Typhi* using the *S.*
178 *Typhi* fimbriae gene target on the multiplex PCR. This participant had the highest three-month anti-Vi
179 IgG and anti-H:d IgG titres among participants submitting stool. (Supplemental Figures 1-3).

180

181 *Figure 1. A. Log anti-Vi IgG concentration at the three month visit among participants who grew Salmonella spp. in stool (purple)*
182 *compared with those who had no growth (turquoise). B. log anti-H:d IgM concentration at the three month visit among participants who*
183 *grew Salmonella spp. in stool (green) compared with those who did not (red). C. log anti-H:d IgG concentration at the three month visit*
184 *among participants who grew Salmonella spp. in stool (brown) and those who did not (black).*

185

186 *Antibody responses*

187 Among participants with persistent fever there was a significant fall in anti-Vi IgG between three and
188 six months (median titre 8.08 to 3.7 EU/ml ($p = <0.000001$, *Wilcoxon signed rank test*). This was not
189 true of participants without persistent fever (median titre 3.7 to 3.7 EU/ml, $p = 0.12$, *Wilcoxon signed*
190 *rank test*) (Figure 2.)

191 *Figure 2. A. log anti-Vi IgG concentration amongst participants with persistent fever, comparing titres at 3 months (lilac) and 6 months*
192 *(turquoise) post-outbreak. B. log anti-Vi IgG concentration amongst participants without persistent fever, comparing titres at 3 months*
193 *(lilac) and 6 months (turquoise) post-outbreak. C. log anti-H:d IgM concentration amongst participants with persistent fever, comparing*
194 *titres at 3 months (beige) and 6 months (yellow) post-outbreak. D. log anti-H:d IgM concentration amongst participants without persistent*
195 *fever, comparing titres at 3 months (beige) and 6 months (yellow) post outbreak. E. log anti-H:d IgG concentration amongst participants*
196 *without persistent fever, comparing titres at 3 months (green) and 6 months (purple) post-outbreak. F. log anti-H:d IgM concentration*
197 *amongst participants without persistent fever, comparing titres at 3 months (green) and 6 months (purple) post-outbreak. All graphs: red*
198 *crossbar shows median antibody concentration; brackets show p-values (Wilcoxon signed rank test).*

199

200 Among participants with persistent fever there was a significant fall in anti-H:d IgG between three
201 and six months (median titre 87.8 to 77.4 EU/ml ($p = 0.0002$, *Wilcoxon signed rank test*). Among
202 participants without persistent fever, there was also a significant fall in anti-H:d IgG between three
203 and six months (median titre 82.4 to 79.2 EU/ml, $p = 0.006$, *Wilcoxon signed rank test*) (Figure 2.)
204 There was no significant change in anti-H:d IgM between three and six months, either among those
205 with persistent fever (median titre 55.2 to 54.2 EU/ml ($p = 0.33$, *Wilcoxon signed rank test*) or
206 without persistent fever (median titre 52.1 to 55.3 EU/ml ($p = 0.42$, *Wilcoxon signed rank test*).
207 (Figure 2.)

208

209 *Environmental Sampling*

210 Non-typhoidal *Salmonella* was identified from tap water in the kitchen of the nursing school and in
211 water from Malosa dam. No *S. Typhi* was identified.

212 *Discussion*

213 Our study shows that, even in a population enriched through the circumstances of an outbreak, sero-
214 surveillance could not identify culture-confirmed shedding of *S. Typhi*. Sero-surveillance combined
215 with PCR may have identified one participant shedding *S. Typhi*. Anti-Vi IgG titres fell amongst
216 participants reporting persistent fever during the outbreak. Anti-H:d IgG titres fell amongst
217 participants with and without persistent fever. There was no change in anti-H:d IgM, irrespective of
218 fever status. We did not find an environmental reservoir of *S. Typhi*, but non-typhoidal *salmonellae*
219 were present in water samples from the reservoir supplying the nursing school, and a tap in the
220 kitchen. The presence of these bacteria indicate contamination and under-treatment of the water
221 supply, and represent a possible source of the outbreak.

222 As our population was pre-defined, we could not perform an *a priori* power calculation. Our study
223 population was young (mean 23.5 years). We expect low rates of biliary pathology in the population
224 based on discussions with surgical colleagues working in the area. A similar study design might have

225 detected *S. Typhi* shedding amongst an older cohort, or in an endemic setting where rates of biliary
226 disease are high.

227 Participants from the Nursing College were on clinical placement in multiple institutions across
228 Southern Malawi. This made enrolment and follow-up challenging: we were unable to obtain stool
229 samples from all the participants that we identified in the highest and lowest anti-Vi IgG titre groups.
230 Given the intermittent nature of shedding, several samples over time would have increased our
231 chances of detecting *S. Typhi* by culture. One participant was identified as having PCR amplification
232 of the *fimbriae* target. This suggests that they may have been carrying / shedding *S. Typhi*, but this
233 could not be verified through culture confirmation. This participant had the highest anti-Vi IgG and
234 anti-H:d IgG titres of all those who submitted stool.

235 The fall in anti-Vi IgG and anti-H:d IgG suggests that a peak titre is reached within the post outbreak
236 surveillance period encompassed by our study, and that titres have fallen six months post exposure. It
237 is possible that anti-Vi IgG is more specific to febrile typhoid illness, or that anti-H:d IgG falls more
238 swiftly after exposure and so an effect was demonstrable across the entire cohort. This would be in
239 keeping with findings from a human challenge model (22). The static anti-H:d IgM concentration
240 suggests that any change in titre precipitated by the outbreak has been and gone at three months.

241 The Vi (virulence) antigen comprises a polysaccharide expressed on the surface of *S. Typhi*, as well
242 as *Salmonella* Paratyphi C, *Citrobacter freundii* and *Salmonella* Dublin (23, 24). IgG antibodies to
243 the Vi antigen have been detected in high titres among microbiologically confirmed shedders of *S.*
244 *Typhi* (14, 25, 26). *S. Typhi* shedders have been identified through their high anti-Vi titre in the
245 context of two outbreaks in the United States (12, 13). Yet the role of anti-Vi IgG for population
246 screening for Typhoid shedding remains unclear: a 2004 study obtained sera from 3209 adults in a
247 Typhoid-endemic area (Vietnam). Multiple rectal swabs were taken from 103 participants with the
248 highest anti-Vi IgG titres at different time points and no *S. Typhi* was isolated (15). Although we
249 obtained fewer faecal specimens, our study population was ‘enriched’ by a known recent exposure to
250 typhoid. The paucity of *S. Typhi* detection in both settings suggests that anti-Vi IgG might be elevated
251 for reasons other than biliary carriage, such as cross-reactivity with other bacteria that express the Vi

252 antigen, or convalescence from acute typhoid fever. It is plausible that both factors would be more
253 significant in areas of the world where typhoid fever is endemic, explaining the geographical
254 discrepancy. A Chilean study comparing anti-Vi IgG amongst bacteriologically proven *S. Typhi*
255 carriers and healthy control subjects and those with acute typhoid fever supports our finding that anti-
256 Vi IgG is a non-specific marker in an endemic setting: although the authors demonstrated higher
257 antibody titre among the shedders, one quarter of chronic carriers did not have a high anti-Vi IgG titre
258 (14).

259 A recent study utilising culture confirmed carriers who underwent cholecystectomy in Nepal found 13
260 putative antigens in sera that were expressed highly in the carrier state, and which might bear closer
261 scrutiny in future studies looking for shedding (27). Future studies should focus on robust
262 microbiological confirmation of *S. Typhi* shedding status to provide clear comparators for prospective
263 serologic markers. The detection of carriers will require repeated stool sampling over time, and newer
264 PCR techniques may increase sensitivity over culture alone (19, 28).

265 Despite the success of conjugate typhoid vaccines in preventing typhoid cases, the recent cluster
266 randomised trial in Bangladesh has yet to show significant indirect protection (29). Wider public
267 health measures, including identifying those who continue to shed *S. Typhi* after infection, remain key
268 to reducing transmission and to ultimately eradicating typhoid.

269 Funding

270 This research was supported by a grant from the Bill and Melinda Gates Foundation.

271 References

- 272 1. Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. The global
273 burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease
274 Study 2017. *The Lancet Infectious Diseases*. 2019;19(4):369-81.
- 275 2. Feasey NA, Gaskell K, Wong V, Msefula C, Selemani G, Kumwenda S, et al. Rapid
276 emergence of multidrug resistant, H58-lineage *Salmonella typhi* in Blantyre, Malawi. *PLoS neglected*
277 *tropical diseases*. 2015;9(4):e0003748.
- 278 3. Davis WW, Chonzi P, Masunda KP, Shields LM, Mukeredzi I, Manangazira P, et al. Notes
279 from the field: typhoid fever outbreak—Harare, Zimbabwe, October 2016–March 2017. *Morbidity*
280 *and Mortality Weekly Report*. 2018;67(11):342.
- 281 4. Hendriksen RS, Leekitcharoenphon P, Lukjancenko O, Lukwesa-Musyani C, Tambatamba B,
282 Mwaba J, et al. Genomic signature of multidrug-resistant *Salmonella enterica* serovar *Typhi* isolates

- 283 related to a massive outbreak in Zambia between 2010 and 2012. *Journal of clinical microbiology*.
284 2015;53(1):262-72.
- 285 5. Lutterloh E, Likaka A, Sejvar J, Manda R, Naiene J, Monroe SS, et al. Multidrug-resistant
286 typhoid fever with neurologic findings on the Malawi-Mozambique border. *Clinical infectious*
287 *diseases*. 2012;54(8):1100-6.
- 288 6. Park SE, Pham DT, Boinett C, Wong VK, Pak GD, Panzner U, et al. The phylogeography and
289 incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. *Nature communications*.
290 2018;9(1):1-10.
- 291 7. Pitzer VE, Feasey NA, Msefula C, Mallewa J, Kennedy N, Dube Q, et al. Mathematical
292 modeling to assess the drivers of the recent emergence of typhoid fever in Blantyre, Malawi. *Clinical*
293 *Infectious Diseases*. 2015;61(suppl_4):S251-S8.
- 294 8. Braddick MR, Crump BJ, Yee ML. How long should patients with *Salmonella typhi* or
295 *Salmonella paratyphi* be followed-up? A comparison of published guidelines. *Journal of Public*
296 *Health*. 1991;13(2):101-7.
- 297 9. Kariuki S, Dyson ZA, Mbae C, Ngetich R, Kawai S, Wairimu C, et al. Multiple introductions
298 of multidrug-resistant typhoid associated with acute infection and asymptomatic carriage, Kenya.
299 bioRxiv. 2021.
- 300 10. Luxemburger C, Duc CM, Lanh MN, Wain J, Hien TT, Simpson JA, et al. Risk factors for
301 typhoid fever in the Mekong delta, southern Viet Nam: a case-control study. *Transactions of the*
302 *Royal Society of Tropical Medicine and Hygiene*. 2001;95(1):19-23.
- 303 11. Crump JA. Progress in typhoid fever epidemiology. *Clinical Infectious Diseases*.
304 2019;68(Supplement_1):S4-S9.
- 305 12. Lin F, Becke J, Groves C, Lim B, Israel E, Becker E, et al. Restaurant-associated outbreak of
306 typhoid fever in Maryland: identification of carrier facilitated by measurement of serum Vi
307 antibodies. *Journal of clinical microbiology*. 1988;26(6):1194-7.
- 308 13. Engleberg N, Barrett T, Fisher H, Porter B, Hurtado E, Hughes J. Identification of a carrier by
309 using Vi enzyme-linked immunosorbent assay serology in an outbreak of typhoid fever on an Indian
310 reservation. *Journal of clinical microbiology*. 1983;18(6):1320-2.
- 311 14. Lanata C, Ristori C, Jimenez L, Garcia J, Levine M, Black R, et al. Vi serology in detection
312 of chronic *Salmonella typhi* carriers in an endemic area. *The Lancet*. 1983;322(8347):441-3.
- 313 15. Gupta A, Thanh NM, Olsen S, Sivapalasingam S, Trinh TM, Lan NP, et al. Evaluation of
314 community-based serologic screening for identification of chronic *Salmonella typhi* carriers in
315 Vietnam. *International journal of infectious diseases*. 2006;10(4):309-14.
- 316 16. Khanam F, Darton TC, Meiring JE, Sarker PK, Biswas PK, Bhuiyan MAI, et al. *Salmonella*
317 *Typhi* stool shedding by enteric fever patients and asymptomatic chronic carriers in an endemic urban
318 setting. *Journal of Infectious Diseases*. 2021.
- 319 17. WHO. Typhoid and other invasive salmonellosis. *Vaccine-Preventable Diseases Surveillance*
320 *Standards*. Geneva, Switzerland: World Health Organization; 2020.
- 321 18. Thieu NTV, Van TT, Tuan AT, Klemm EJ, Minh CNN, Vinh PV, et al. An evaluation of
322 purified *Salmonella Typhi* protein antigens for the serological diagnosis of acute typhoid fever.
323 *Journal of Infection*. 2017;75(2):104-14.
- 324 19. Chirambo AC, Nyirenda TS, Jambo N, Msefula C, Kamng'ona A, Molina S, et al.
325 Performance of molecular methods for the detection of *Salmonella* in human stool specimens.
326 Wellcome open research. 2020;5.
- 327 20. Msefula CL, Olgemoeller F, Jambo N, Segula D, Van Tan T, Nyirenda TS, et al. Ascertaining
328 the burden of invasive *Salmonella* disease in hospitalised febrile children aged under four years in
329 Blantyre, Malawi. *PLoS neglected tropical diseases*. 2019;13(7):e0007539.

- 330 21. Team RC. R: a language and environment for statistical computing. 4.1.0 ed. Vienna,
331 Austria: R Foundation for Statistical Computing; 2021.
- 332 22. Darton TC, Baker S, Randall A, Dongol S, Karkey A, Voysey M, et al. Identification of novel
333 serodiagnostic signatures of typhoid fever using a Salmonella proteome array. *Frontiers in*
334 *microbiology*. 2017;8:1794.
- 335 23. Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. Salmonella chronic
336 carriage: epidemiology, diagnosis, and gallbladder persistence. *Trends in microbiology*.
337 2014;22(11):648-55.
- 338 24. Hu X, Chen Z, Xiong K, Wang J, Rao X, Cong Y. Vi capsular polysaccharide: Synthesis,
339 virulence, and application. *Critical reviews in microbiology*. 2017;43(4):440-52.
- 340 25. Nolan CM, Feeley JC, White Jr PC, Hambie EA, Brown SL, Wong K-H. Evaluation of a new
341 assay for Vi antibody in chronic carriers of Salmonella typhi. *Journal of clinical microbiology*.
342 1980;12(1):22-6.
- 343 26. Losonsky GA, Ferreccio C, Kotloff KL, Kaintuck S, Robbins J, Levine M. Development and
344 evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic
345 Salmonella typhi carriers. *Journal of clinical microbiology*. 1987;25(12):2266-9.
- 346 27. Charles RC, Sultana T, Alam MM, Yu Y, Wu-Freeman Y, Bufano MK, et al. Identification of
347 immunogenic Salmonella enterica serotype Typhi antigens expressed in chronic biliary carriers of S.
348 Typhi in Kathmandu, Nepal. *PLoS neglected tropical diseases*. 2013;7(8):e2335.
- 349 28. Nair S, Patel V, Hickey T, Maguire C, Greig DR, Lee W, et al. Real-time PCR assay for
350 differentiation of typhoidal and nontyphoidal Salmonella. *Journal of clinical microbiology*.
351 2019;57(8):e00167-19.
- 352 29. Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas PK, Bhuiyan AI, et al. Protection by
353 vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban
354 Bangladesh: a cluster-randomised trial. *The Lancet*. 2021;398(10301):675-84.

355

356 *Supplemental Figures*

357 *Supplemental Figure 1. A. Log anti-Vi IgG concentration at the three month visit among participants who did and did not amplify the*
358 *fimbriae PCR target from stool. Green coloured dots represent participants who were culture-negative for Salmonella spp. from stool,*
359 *turquoise coloured dots represent those who were culture-positive for Salmonella spp from stool. B. log anti-H:d IgM at the three month*
360 *visit among participants who did and did not amplify the fimbriae PCR target from stool. Yellow coloured dots represent participants who*
361 *were culture-negative for Salmonella spp. from stool, purple coloured dots represent those who were culture-positive for Salmonella spp*
362 *from stool. C. log anti-H:d IgG at the three month visit among participants who did and did not amplify the fimbriae PCR target from stool.*
363 *Orange coloured dots represent participants who were culture-negative for Salmonella spp. from stool, grey coloured dots represent those*
364 *who were culture-positive for Salmonella spp from stool.*





Figure 2



Supplementary Figure 1




Figure 1